Business Wire

Clinical Data Shows Noxopharm’s Veyonda® May Prevent Cytokine Storm

27.4.2021 15:00:00 EEST | Business Wire | Press release

Share

Australian clinical-stage drug development company Noxopharm Limted (ASX:NOX) today announced that in a cohort of 18 patients with moderately severe cases of COVID-19, interim data in its NOXCOVID study suggests Veyonda provides protection against progression of the severe inflammation associated with a worsening of the disease.

“Until enough people are vaccinated to achieve global herd immunity in the face of waves of emerging mutant strains of the virus, millions of people are likely to continue to suffer severe COVID-19 disease involving major disabilities and death,” said Noxopharm CEO Graham Kelly. “That is where we see Veyonda playing a key role, with its STING blocking action stopping the destructive inflammatory process in patients with moderate COVID-19. The interim data released today points to Veyonda delivering on this promise.”

The major challenge for hospital services during the current pandemic is the high level of care required for those patients experiencing rapid deterioration of lung function, leading to acute respiratory distress syndrome, septic shock, and major disabilities or death. A key factor associated with disease worsening is the excessive production of inflammatory factors normally invoked to facilitate tissue repair and combat infection in a process known as the cytokine storm.

Biomarker data from the top Veyonda dose cohort is expected within the next few weeks. That will be followed by a review of the final clinical data on completion of treatment of the final patient. Clinical status (WHO COVID-19 grade, comorbidities) and other therapies will be considered, and after reviewing all the data, the Company will then consult with government, regulatory, medical, and business development advisors.

About Noxopharm

Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and septic shock. Veyonda® is the Company’s first pipe-line drug candidate currently in Phase 2 clinical trialing. Veyonda has two main drug actions – a moderating effect on the ceramide/sphingosine-1-phosphate balance and inhibition of STING signaling. Activity against the former target contributes to its dual-acting oncotoxic and immuno-oncology functions designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapies, radiotherapy and immune checkpoint inhibitors. Activity against the latter target provides an anti-inflammatory effect, also contributing to an anti-cancer action, but also potentially blocking septic shock.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jane Byram
SCORR Marketing
+1-512-626-2758
jane@scorrmarketing.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Update Settlement Infrastructure for New Games, Build Multi-Rail Trust Layer, and Close the Accessibility Gap in AI Economy: Ant International’s Peng Yang at SFF 202619.11.2026 14:05:00 EET | Press release

At the Singapore FinTech Festival, Ant International CEO Peng Yang (YP) joined Javier Pérez-Tasso of Swift and Surendra Rosha of HSBC on the panel “From Digital to Intelligent: Who Will Build the Next Financial System?”, moderated by Arjun Vir Singh of Arthur D. Little. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119101038/en/ Ant International at the Singapore Fintech Festival 2026 YP highlighted three critical angles to tackle the future financial system: How should settlement infrastructure evolve in the AI + blockchain era to establish new game rules? How to build cross-rail, cross-modal trust for the agentic economy? How to mainstream inclusion into AI design to close the accessibility gap for SMEs? The Missing Debate: Rewiring settlement infrastructure The four-party payment model — issuer, acquirer, network, regulator — has served as a mature bedrock for traditional economy. However, would we still need the acqu

NIQ Appoints Danny Lange and Chris Tung to Board of Directors19.11.2026 13:45:00 EET | Press release

NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced that Danny Lange and Chris Tung have been appointed to its Board of Directors, effective Nov. 18, 2026. Lange brings more than three decades of technology leadership, including senior roles building and scaling artificial intelligence and machine learning capabilities at Google, Unity, Uber, Amazon and Microsoft. Tung brings extensive operating, consumer and digital commerce experience across Greater China and Asia Pacific through leadership roles at Shangri-La Asia, Alibaba, PepsiCo, L’Oréal and other global businesses. Together, their experience strengthens the Board’s perspective as NIQ advances its AI strategy and expands its impact across global markets. “Danny and Chris bring expertise that directly aligns with where NIQ is going,” said Jim Peck, Executive Chairman and Chief Executive Officer of NIQ. “Danny has spent his career building AI and machine learning capabilities at scale. Chris brings deep

Compass Pathways to Participate in 9th Annual Evercore Healthcare Conference on December 119.11.2026 13:30:00 EET | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the 9th Annual Evercore Healthcare Conference on December 1, 2026 and will participate in a fireside chat at 3:25pm ET. A live audio webcast of the fireside chat will be accessible at the following link: https://event.summitcast.com/view/FkwyWrnNgoveMhBfJS2NCC/We7ydUWZPZM5Wf4zVRNZnZ A replay of the webcast will be accessible for 30 days following each event at the “Events” page of the Investors section of the Compass website. About Compass Pathways We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Our initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treatment under evaluation f

SRM and Ridgemont Equity Partners Announce Strategic Partnership to Accelerate Next Phase of Growth19.11.2026 13:00:00 EET | Press release

Strategic Resource Management (SRM), a trusted, tech-enabled advisory firm serving financial institutions globally, today announced a strategic investment from Ridgemont Equity Partners, a middle market private equity investor. Building on over three decades of experience serving financial institutions and fintechs, this recapitalization aims to further strengthen SRM’s capabilities, talent, systems, and resources. Brad Downs, Chief Executive Officer and Chairman, and SRM’s existing leadership team will continue to lead the company into its next phase of growth. “SRM is a market-leading advisory firm with a strong reputation and proven track record, and is led by a very experienced executive team with a passion for delivering measurable results and meaningful business impact. SRM is an excellent fit with our experience in Business and Technology Services, and we see multiple ways to add value alongside the team as SRM’s first institutional investor. We’re excited to partner with Brad D

Pretium Expands Real Estate Debt Platform19.11.2026 13:00:00 EET | Press release

Pretium, a specialized investment firm with approximately $70 billion in assets under management, today announced it is expanding its residential real estate debt platform, further enabling the flow of capital to real estate investors, developers and homebuilders. Since launching its residential debt platform in December 2024, Pretium has lent approximately $8 billion for the purpose of new housing construction and the renovation of existing homes. Building on its existing model, Pretium is adding the team from Hilltop Capital Partners (“Hilltop”), a specialized U.K.-based institutional capital advisor, investment manager and principal lender, to its vertically integrated residential real estate platform. Led by Paul Oberschneider and Tiger Craft, Hilltop has grown into a leading platform for residential development finance across the U.K since its founding in 2019. “The U.K. faces a housing shortage of approximately four to five million homes, and the Hilltop team has built an impress

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye